Biocryst Pharmaceuticals Inc.

NASDAQ:BCRX 3:59:56 PM EDT

14.94

-0.44 (-2.86%)

4:22:37 PM EDT: $15.00 +0.06 (+0.40%)

Market Cap (Intraday)	2.67B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$39.56 Million
Adjusted EPS	-$0.29

See more estimates

10-Day MA	$14.94
50-Day MA	$14.97
200-Day MA	$13.59

See more pivots

Biocryst Pharmaceuticals Inc. Stock, NASDAQ:BCRX

4505 Emperor Boulevard, Suite 200, Durham, North Carolina 27703-8457

United States of America

Phone: +1.919.859.1302

Number of Employees: 246

http://www.biocryst.com

Description

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.